Post Profile






Bristol-Myers stops kidney cancer drug test after early success

(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals.
read more

share

Related Posts


Bristol's drug cocktail cuts kidney cancer death risk 37 percent

Health : Reuters: Health

MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.

Bristol-Myers kidney cancer drug meets main goal of late-stage trial

Health : Reuters: Health

(Reuters) - Bristol-Myers Squibb Co said on Thursday its combination drug to treat a type of kidney cancer met one of the main goals of overall survival in a late-stage study.

Multigene Test May Help Identify Hereditary Kidney Cancers

Health : Newswise Medical News

A multigene panel test could be a useful diagnostic tool to help clinicians identify patients with a hereditary kidney cancer syndrome, according to the results of a study published in Cancer.

Combination Immunotherapy Improves Kidney Cancer Survival

Health : Newswise Medical News

A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presente...

Bristol-Myers kidney cancer drug meets early success, study stopped

Health : Reuters: Health

(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial early, despite having reported mixed results on other main goa...

Comments


Copyright © 2016 Regator, LLC